Key points are not available for this paper at this time.
The use of TDF-FTC before and after sexual activity provided protection against HIV-1 infection in men who have sex with men. The treatment was associated with increased rates of gastrointestinal and renal adverse events. (Funded by the National Agency of Research on AIDS and Viral Hepatitis ANRS and others; ClinicalTrials.gov number, NCT01473472.).
Molina et al. (2015) studied this question.